Elaprase launched for Hunter syndrome

Shire has launched Elaprase (idursulfase), indicated for the long-term treatment of patients with Hunter syndrome (also known as mucopolysaccharidosis II).

Elaprase is administered at a dose of 0.5mg/kg weekly by intravenous infusion over three hours. The infusion time can be gradually reduced to one hour if no infusion-associated reactions occur.

Idursulfase is the first human enzyme replacement therapy for Hunter syndrome. It is supplied in single vial packs, each vial containing 6mg of idursulfase in 3ml concentrate for solution for infusion.

Further information: Shire 01256 894000

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...